KEYTRUDA (Merck Sharp & Dohme Corp.)


Welcome to the PulseAid listing for the KEYTRUDA drug offered from Merck Sharp & Dohme Corp.. This Programmed Death Receptor-1 Blocking Antibody [EPC],Programmed Death Receptor-1-directed Antibody Interactions [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: Merck Sharp & Dohme Corp.
NON-PROPRIETARY NAME: pembrolizumab
SUBSTANCE NAME: PEMBROLIZUMAB
TYPE: HUMAN PRESCRIPTION DRUG
PHARMA CLASS: Programmed Death Receptor-1 Blocking Antibody [EPC],Programmed Death Receptor-1-directed Antibody Interactions [MoA]
ROUTE: INTRAVENOUS
DOSAGE FORM: INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
MARKETING CATEGORY NAME: BLA
START MARKETING DATE: 2014-09-04
END MARKETING DATE: 0000-00-00


KEYTRUDA HUMAN PRESCRIPTION DRUG Details:

Item DescriptionKEYTRUDA from Merck Sharp & Dohme Corp.
LABELER NAME: Merck Sharp & Dohme Corp.
DEA SCHEDULE:
ACTIVE STRENGTH: 50(mg/2mL)
START MARKETING DATE: 2014-09-04
END MARKETING DATE: 0000-00-00
PRODUCT ID: 0006-3029_8435cc61-92b4-4718-ab09-e42585e92d19
PRODUCT NDC: 0006-3029
APPLICATION NUMBER: BLA125514

Other PEMBROLIZUMAB Pharmaceutical Manufacturers / Labelers:

Manufacturer / LabelerProprietary Name
Merck Sharp & Dohme Corp.KEYTRUDA